Skip to content

Pipeline

A broad pipeline, one platform

Eleven oncology indications and four infectious-disease programs. Stages shown reflect preclinical and IND-enabling progress; all candidates are investigational.

Oncology

Eleven indications, led by OTM001

Breast cancer (OTM001) is furthest along — through Pre-Clinical and into IND-Enabling.

  • Breast Cancer

    OTM001

    Through IND-Enabling

    Breast Cancer: through IND-Enabling stage.

  • Liver

    Through Pre-Clinical

    Liver: through Pre-Clinical stage.

  • Prostate

    Through Pre-Clinical

    Prostate: through Pre-Clinical stage.

  • Lung Carcinoma

    Through Pre-Clinical

    Lung Carcinoma: through Pre-Clinical stage.

  • Bladder

    Through Pre-Clinical

    Bladder: through Pre-Clinical stage.

  • Cervical

    Through Pre-Clinical

    Cervical: through Pre-Clinical stage.

  • Melanoma

    Through Pre-Clinical

    Melanoma: through Pre-Clinical stage.

  • B-Cell Leukemia

    Through Pre-Clinical

    B-Cell Leukemia: through Pre-Clinical stage.

  • Head & Neck

    Through Pre-Clinical

    Head & Neck: through Pre-Clinical stage.

  • Ovarian

    Through Pre-Clinical

    Ovarian: through Pre-Clinical stage.

  • Glioblastoma

    Through Pre-Clinical

    Glioblastoma: through Pre-Clinical stage.

Infectious Disease

Four programs in development

Applying the same precision platform beyond oncology, led by RSV.

  • RSV

    Through Pre-Clinical

    RSV: through Pre-Clinical stage.

  • Zika

    Through Pre-Clinical

    Zika: through Pre-Clinical stage.

  • Ebola

    Through Pre-Clinical

    Ebola: through Pre-Clinical stage.

  • COVID-19

    Through Pre-Clinical

    COVID-19: through Pre-Clinical stage.

Lead-program spotlight

First-in-Human study — TNBC

A neoadjuvant, intratumoral (IT) injection of pDNA-LNP for triple-negative breast cancer: a 3-patient study with a Florida-based CRO, initiating Q2 2026.

  1. Complete

    Preclinical & IND-Enabling

    Proof-of-concept across 24 cell lines, animal models, tumoroids, and organ-on-a-chip studies.

  2. Next milestone

    First-in-Human (FIH) — Q2 2026

    Neoadjuvant intratumoral injection of pDNA-LNP for TNBC. A 3-patient study with a Florida-based CRO.

  3. Future

    Subsequent Clinical Phases

    Phased clinical evaluation to follow, contingent on FIH outcomes and regulatory guidance.

Timeline reflects planned First-in-Human timing only. OTM001 is investigational and has not been approved by any regulatory authority.